Related Experiment Videos
Immunotoxins containing single-chain ribosome-inactivating proteins
Cancer Treatment and Research
|January 1, 1988
Summary
Single-chain ribosome-inactivating proteins show promise in immunoconjugates for cancer therapy, demonstrating antitumor efficacy in animal models. However, potential immunogenicity of these immunotoxin (IT) conjugates may limit clinical applications.
Area of Science:
- Biochemistry
- Immunology
- Oncology
Background:
- Single-chain ribosome-inactivating proteins (RIPs) possess cytotoxic properties.
- Immunoconjugates (ITs) utilize antibodies to target RIPs to cancer cells.
- Gelonin serves as an example RIP for IT development.
Purpose of the Study:
- To review the distribution, biological role, and mechanism of action of single-chain RIPs.
- To evaluate the potential of ITs made with single-chain RIPs for cancer treatment.
- To address the immunogenicity concerns associated with ITs.
Main Methods:
- Purification of gelonin as a representative single-chain RIP.
- Construction and in vitro cytotoxicity assessment of ITs.
- Evaluation of IT antitumor efficacy in animal tumor models.
Main Results:
- ITs with single-chain RIPs exhibit specific in vitro cytotoxicity comparable to ricin A-chain ITs.
- The most potent ITs demonstrate significant antitumor efficacy in various animal models.
- Both antibody and toxin components of ITs are potentially immunogenic.
Conclusions:
- Single-chain RIP-based ITs show preclinical promise for cancer therapy.
- Host immune responses to IT components may limit clinical efficacy.
- Utilizing immunologically distinct RIPs sequentially could overcome immunogenicity issues.